<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109247">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885364</url>
  </required_header>
  <id_info>
    <org_study_id>KNUH 2013-05-003-001</org_study_id>
    <nct_id>NCT01885364</nct_id>
  </id_info>
  <brief_title>Esmolol Pretreatment on Pain During Injection of Propofol</brief_title>
  <official_title>Esmolol Pretreatment on Pain During Injection of Propofol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyungpook National University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain on injection of propofol is a common side effect. The present study was designed to
      investigate the effect of esmolol on pain on propofol injection and to compare it with
      remifentanil and placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a double-blind, prospective trial, 120 patients scheduled to undergo elective surgery
      were randomized to receive normal saline (n=30), remifentanil 0.35 Î¼g/kg (n=30), esmolol 0.5
      mg/kg (n=30), or Esmolol 1mg/kg (n=30) as pretreatment. Thirty seconds after pretreatment,
      25% of the total calculated dose of propofol (2 mg/kg) was administrated into a dorsal hand
      vein. Ten seconds after propofol had been given at the rate of 0.5 ml/sec pain was assessed
      on a four-point scale (0=none, 1 = mild, 2= moderate, 3= severe).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Pain on injection of propofol</measure>
    <time_frame>10 seconds after injection of 25% of the total calculated dose of propofol (2 mg/kg)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Thirty seconds after pretreatment, 25% of the total calculated dose of propofol (2 mg/kg) was administrated into a dorsal hand vein. Ten seconds after injection of propofol, pain was assessed on a four-point scale (0=none, 1 = mild, 2= moderate, 3= severe).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo &amp; propofol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pretreatment with normal saline before injection of propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>esmolol 0.05 mg/kg &amp; propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pretreatment with esmolol 0.05 mg/kg before injection of propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>esmolol 1 mg/kg &amp; propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pretreatment with esmolol 1 mg/kg before injection of propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>remifentanil 0.35 ug/kg &amp; propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pretreatment with remifentanil 0.35 ug/kg before injection of propofol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>intravenous injection with normal saline before injection of propofol</description>
    <arm_group_label>Placebo &amp; propofol</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>intravenous injection with remifentanil 0.5 mg/kg before injection of propofol</description>
    <arm_group_label>esmolol 0.05 mg/kg &amp; propofol</arm_group_label>
    <arm_group_label>esmolol 1 mg/kg &amp; propofol</arm_group_label>
    <other_name>breviblock</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>intravenous injection with remifentanil 0.35 ug/kg before injection of propofol</description>
    <arm_group_label>remifentanil 0.35 ug/kg &amp; propofol</arm_group_label>
    <other_name>ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>intravenous injection after pretreatment</description>
    <arm_group_label>Placebo &amp; propofol</arm_group_label>
    <arm_group_label>esmolol 0.05 mg/kg &amp; propofol</arm_group_label>
    <arm_group_label>esmolol 1 mg/kg &amp; propofol</arm_group_label>
    <arm_group_label>remifentanil 0.35 ug/kg &amp; propofol</arm_group_label>
    <other_name>diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged 19-60 years, American Society of Anesthesiologists (ASA) physical
             status I and II, scheduled for elective surgery under general anesthesia

        Exclusion Criteria:

          -  Patients with cardiovascular, neurological or psychiatric disorder problem, patients
             who received the analgesic or sedative medications within the last 24 hours, and
             pregnancy were excluded
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Younghoon Jeon, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kibum Park, Dr</last_name>
      <phone>82-53-420-5863</phone>
      <email>pakkibum@naver.com</email>
    </contact>
    <investigator>
      <last_name>Younghoon Jeon, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 25, 2013</lastchanged_date>
  <firstreceived_date>June 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University</investigator_affiliation>
    <investigator_full_name>Younghoon Jeon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>esmolol</keyword>
  <keyword>pain</keyword>
  <keyword>propofol</keyword>
  <keyword>remifentanil</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
